Review
Biochemistry & Molecular Biology
Stephen D. H. Malnick, Pavel Alin, Marina Somin, Manuela G. Neuman
Summary: Both alcohol-induced liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) involve abnormal fat accumulation in the liver, potentially caused by excessive alcohol consumption and the combination of alcohol consumption and medications. The liver pathology is similar in both conditions, progressing from simple steatosis to inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Evaluating the medical history of alcohol consumption, laboratory markers, AST/ALT ratio, and features of the metabolic syndrome can help estimate the contribution of alcohol intake and metabolic syndrome to liver steatosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Surgery
John Reynolds, Noel E. Donlon, Jessie A. Elliott, Brendan Moran, Hugo Temperley, Tim S. Nugent, Maria Davern, Sinead King, Melissa Conroy, Joanne Lysaght, Narayanasamy Ravi, Carmel Ryan, Stephen Finn, Suzanne Norris, Clare L. Donohoe
Summary: This study establishes for the first time the incidence and clinical impact of NAFLD in EAC patients undergoing surgery and highlights no major impact on oncologic outcomes, nor in the severity of complications.
WORLD JOURNAL OF SURGERY
(2023)
Review
Nutrition & Dietetics
Ludovico Abenavoli, Tiziana Larussa, Alessandro Corea, Anna Caterina Procopio, Luigi Boccuto, Marcello Dallio, Alessandro Federico, Francesco Luzza
Summary: NAFLD, characterized by a wide spectrum of liver disorders, is considered a major public health issue globally. Polyphenols, known for their anti-inflammatory and antioxidant properties, are believed to have potential benefits in preventing and treating NAFLD, though limited human clinical trials are available.
Article
Gastroenterology & Hepatology
Ramy Younes, Olivier Govaere, Salvatore Petta, Luca Miele, Dina Tiniakos, Alastair Burt, Ezio David, Fabio Maria Vecchio, Marco Maggioni, Daniela Cabibi, Duncan McLeod, Maria Jesus Pareja, Anna Ludovica Fracanzani, Rocio Aller, Chiara Rosso, Javier Ampuero, Rocio Gallego-Duran, Angelo Armandi, Gian Paolo Caviglia, Marco Y. W. Zaki, Antonio Liguori, Paolo Francione, Grazia Pennisi, Antonio Grieco, Giovanni Birolo, Piero Fariselli, Mohammed Eslam, Luca Valenti, Jacob George, Manuel Romero-Gomez, Quentin Mark Anstee, Elisabetta Bugianesi
Summary: Lean Caucasian subjects with NAFLD may progress to advanced liver disease, develop metabolic comorbidities, and experience cardiovascular disease and liver-related mortality, independent of longitudinal progression to obesity and PNPLA3 genotype. These patients represent one end of a wide spectrum of phenotypic expression of NAFLD.
Review
Biochemistry & Molecular Biology
Daryl Ramai, Waqqas Tai, Michelle Rivera, Antonio Facciorusso, Nicola Tartaglia, Mario Pacilli, Antonio Ambrosi, Christian Cotsoglou, Rodolfo Sacco
Summary: NASH is a chronic and progressive form of NAFLD, with a global increasing incidence that poses a threat to public health by potentially leading to HCC. Recent research defines a multi-hit model to demonstrate the complexity of pathways involved in the progression from NASH to HCC.
Review
Medicine, General & Internal
Elizabeth E. Powell, Vincent Wai-Sun Wong, Mary Rinella
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common global health issue with significant associations with metabolic syndrome and type 2 diabetes, leading to serious complications like cirrhosis and hepatocellular carcinoma. While cardiovascular disease and extrahepatic malignancy are the main causes of death in NAFLD patients, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality.
Review
Biochemistry & Molecular Biology
Carlos Jimenez-Cortegana, Alba Garcia-Galey, Malika Tami, Pilar del Pino, Isabel Carmona, Soledad Lopez, Gonzalo Alba, Victor Sanchez-Margalet
Summary: NAFLD affects a quarter of the global population and poses a significant health and economic burden across all countries. The lack of approved pharmacotherapy and well-established diagnostic strategies for this disease highlights the urgency for further research and management efforts. Studies have shown a strong relationship between the hormone leptin and the development of NAFLD, suggesting potential advancements in disease management through further investigation of its role.
Article
Multidisciplinary Sciences
Minxuan Xu, Jun Tan, Wei Dong, Benkui Zou, Xuepeng Teng, Liancai Zhu, Chenxu Ge, Xianling Dai, Qin Kuang, Shaoyu Zhong, Lili Lai, Chao Yi, Tingting Tang, Junjie Zhao, Longyan Wang, Jin Liu, Hao Wei, Yan Sun, Qiufeng Yang, Qiang Li, Deshuai Lou, Linfeng Hu, Xi Liu, Gang Kuang, Jing Luo, Mingxin Xiong, Jing Feng, Chufeng Zhang, Bochu Wang
Summary: This study reveals that Trim31 acts as an endogenous inhibitor of Rhbdf2 in mice, mitigating the development of NASH and potentially serving as a therapeutic target for treating NAFLD/NASH and associated metabolic disorders.
NATURE COMMUNICATIONS
(2022)
Review
Medicine, General & Internal
Lorenz M. W. Holzner, Andrew J. Murray
Summary: NAFLD and NASH are major public health concerns with limited treatment options. Studies show that HIF plays important roles in modulating these diseases, potentially aiding in the development of new therapeutic strategies.
FRONTIERS IN MEDICINE
(2021)
Review
Medicine, Research & Experimental
Samar H. Gerges, Sara A. Wahdan, Doaa A. Elsherbiny, Ebtehal El-Demerdash
Summary: NAFLD is a disorder characterized by excessive fat accumulation in the liver, which can progress to NASH, accompanied by inflammation and fibrosis. The pathophysiology of NAFLD and NASH involves a complex interplay between metabolic, environmental, and genetic factors. Currently, there is no FDA-approved treatment for NAFLD and NASH, with off-label medications and hepatoprotective agents being used instead.
Article
Medicine, Research & Experimental
Yiyuan Zheng, Chaoyuan Huang, Lina Zhao, Youlan Chen, Fengbin Liu
Summary: The study found that UA could provide dual protective functions on metabolic dysfunction and liver hypoxia by regulating IGF-IR and HIF-1 signaling pathways, making it an effective option for the treatment of NASH.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Environmental Sciences
Alexey A. Tinkov, Michael Aschner, Abel Santamaria, Alfred R. Bogdanov, Yousef Tizabi, Miriam B. Virgolini, Ji-Chang Zhou, Anatoly V. Skalny
Summary: The objective of this study was to review existing epidemiological and laboratory findings supporting the role of toxic metal exposure in non-alcoholic fatty liver disease (NAFLD). The existing studies demonstrate a link between exposure to cadmium, lead, arsenic, and mercury and an increased risk of NAFLD, as well as altered liver injury markers. Laboratory studies also show that metal exposure leads to hepatic lipid accumulation and affects metabolic pathways and inflammatory response.
ENVIRONMENTAL RESEARCH
(2023)
Article
Biotechnology & Applied Microbiology
Qingfu Zhu, Hengrui Li, Zheng Ao, Hao Xu, Jiaxin Luo, Connor Kaurich, Rui Yang, Pei-Wu Zhu, Sui-Dan Chen, Xiao-Dong Wang, Liang-Jie Tang, Gang Li, Ou-Yang Huang, Ming-Hua Zheng, Hui-Ping Li, Fei Liu
Summary: This study investigates the lipid composition of urinary EVs and their potential as biomarkers for NASH detection. By analyzing the lipid profiles, a panel of lipid molecules is identified that can distinguish NASH with high accuracy. These lipid molecules are closely associated with the occurrence and development of NASH.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jeong Woo Kim, Chang Hee Lee, Baek-Hui Kim, Young-Sun Lee, Soon-Young Hwang, Bit Na Park, Yang Shin Park
Summary: This study aimed to evaluate the feasibility of using ultrasonography (US) for predicting non-alcoholic steatohepatitis (NASH) in patients with non-alcoholic fatty liver disease (NAFLD) and to develop various US indices combining US parameters and laboratory data for the detection of NASH. The results showed that the index combining gray-scale US parameters and AST had the best diagnostic performance for detecting NASH in NAFLD patients, suggesting its potential use as an alternative to liver biopsy.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
(2022)
Article
Gastroenterology & Hepatology
Christian Labenz, Karel Kostev, Angelo Armandi, Peter R. Galle, Joern M. Schattenberg
Summary: The study found that hypothyroidism and autoimmune thyroiditis were associated with an increased risk of NAFLD, while hyperthyroidism was associated with a decreased risk of NAFLD.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)